SCHEMBL9939620

SCHEMBL9939620

[CH2]Cc1cn(CCCCCC)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 5/20 0.46
TBXAS1 P24557 1/20 0.43
CPB1 P15086 3/20 0.42
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
HTT P42858 5/20 0.39
LMNA P02545 3/20 0.39
GALR3 O60755 2/20 0.39
POLB P06746 2/20 0.39
ATM Q13315 2/20 0.39
MAPK1 P28482 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
APOBEC3A P31941 2/20 0.39
APOBEC3G Q9HC16 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPT P10636 1/20 0.39
RAD52 P43351 1/20 0.39
PAX8 Q06710 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9939293 1.00 CPB2 (0.46) CPB2TBXAS1CPB1NPC1RAB9A
SCHEMBL9941648 1.00 CPB2 (0.46) CPB2TBXAS1CPB1NPC1RAB9A
SCHEMBL9941754 0.93 CPB2 (0.47) CPB2TBXAS1CPB1LMNAPOLB
SCHEMBL8795862 0.87 CPB2 (0.44) CPB2TBXAS1CPB1NPC1RAB9A
SCHEMBL28878999 0.84 CPB2 (0.47) CPB2TBXAS1CPB1NPC1RAB9A
SCHEMBL4373193 0.81 CPB2 (0.46) CPB2TBXAS1CPB1NPC1RAB9A
SCHEMBL9570115 0.80 CPB2 (0.47) CPB2TBXAS1CPB1NPC1RAB9A
SCHEMBL9597175 0.80 CPB2 (0.47) CPB2TBXAS1CPB1NPC1RAB9A
SCHEMBL8934793 0.79 CPB2 (0.45) CPB2TBXAS1CPB1LMNAPOLB
Bromide SCHEMBL16738793 0.79 CPB2 (0.45) CPB2TBXAS1CPB1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9402914-B2 Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides SIRNA THERAPEUTICS, INC. (US) 2016-08-02 US claimed
US-9402914-B2 Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides SIRNA THERAPEUTICS, INC. (US) 2016-08-02 US disclosed
US-20150165058-A1 MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2015-06-18 US disclosed
US-8901101-B2 Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides SIRNA THERAPEUTICS, INC. (US) 2014-12-02 US disclosed
US-20130289207-A1 MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2013-10-31 US disclosed
WO-2012082574-A1 MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES MERCK SHARP & DOHME CORP. (US) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150165058-A1 MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES PUF60, PHOSPHO1, PARG CPB2 1157/4885TBXAS1 4152/4885CPB1 705/4885
US-20130289207-A1 MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES PUF60, PHOSPHO1, PARG CPB2 1157/4885TBXAS1 4152/4885CPB1 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.